David Allen Reardon MD

Hematologic Oncology, Neuro-Oncology

Clinical Director, Center for Neuro-Oncology Dana-Farber Cancer Institute Boston, MA

450 Brookline Avenue, G460fCenter For Neuro-Oncology, Dana-Farber Cancer InstituteBoston, MA 02215
Phone+1 617-632-6172
Fax+1 617-632-4773

Dr. Reardon is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reardon's full profile Already have an account?

Education & Training

University of MichiganFellowship, Pediatric Hematology/Oncology, 1990 - 1993
Johns Hopkins UniversityResidency, Pediatrics, 1987 - 1989
Tufts University School of MedicineClass of 1986

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2011 - 2027
CT State Medical License 2022 - 2026
NC State Medical License 2000 - 2011
ME State Medical License Active through 2000
TN State Medical License 1995 - 2000
MI State Medical License 1989 - 1998

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) Start of enrollment: 2004 Oct 13
COMPLETED
PHASE2
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
COMPLETED
PHASE1, PHASE2
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
COMPLETED
PHASE1

Publications & Presentations

PubMed

Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.
Diana D Shi, Ester Calvo Fernández, Vinesh T Puliyappadamba, Tyler A Lanman, Yi Xiao
Science Translational Medicine. 2026-08-05
Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy.
Genaro R Villa, Ashish D Patel, David A Reardon, E Antonio Chiocca
Science Translational Medicine. 2026-07-29
Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells.
Adi Nagler, Amit Sud, Jack Y Ghannam, Lucas Pomerance, Camila Robles-Oteiza
Nature Biotechnology. 2026-07-22

Journal Articles

Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with Glioblastoma
David Reardon, MD, JAMA Oncology
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma
David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology

Lectures

Concepts for Immunotherapies in Gliomas
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020

Press Mentions

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-OncologyDecember 3rd, 2025
In Mouse Study, New Gel Therapy Stops Dangerous Brain TumorsApril 26th, 2023
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory BoardMarch 21st, 2022

Grant Support

Understanding and Overcoming T cell Immunosuppression in GlioblastomaBRIGHAM AND WOMEN'S HOSPITAL2020–2025
Translational Clinical Trials For Primary CNS TumorsNational Institute Of Neurological Disorders And Stroke2009–2012
Core--Phase I/II Clinical TrialsNational Cancer Institute2007–2008
Translational Clinical Trials In Neuro-OncologyNational Institute Of Neurological Disorders And Stroke2004–2008
Core-3-Phase I/II Clinical TrialsNational Cancer Institute2004–2006